Next, the results also revealed apM1 +45 TT carriers with HOMA-IR greater than 2.0 had a 5.91-fold (95% CI 2.78-12.54) greater risk, and apM1 GG/GT carriers with HOMA-IR greater than 2.0 had a 4.35-fold (95% CI 2.14-8.85) greater risk of developing MetS as compared to apM1 +45 GG/GT carriers with HOMA-IR less than 2.0, respectively. Here, ADIPOQ is linked to metabolic syndrome.